Dermal 4R-Tau Seeding as a Trial-Ready Biomarker for PSP

Antoine Leuzy, ZRO Imaging

Abstract:

Progressive supranuclear palsy (PSP) is a brain disease that causes falls, difficulty moving the eyes, and problems with speech and thinking. Unlike conditions such as Alzheimer’s disease, PSP lacks reliable and widely accessible tests to confirm the diagnosis in living patients. This makes diagnosis challenging and limits the ability to identify appropriate patients for clinical trials of new treatments.

A promising new approach from the University of Toronto has shown that the misfolded tau protein driving PSP can be detected directly from a small skin sample obtained through a minimally invasive punch biopsy, roughly the size of a pencil eraser. This is made possible by a sensitive laboratory technique called a seeding amplification assay (SAA), which can detect misfolded tau in skin tissue with high accuracy. Early results showed it correctly identified PSP in nearly 9 out of 10 patients confirmed after death.

We propose to validate this skin-based tau test across complementary groups. First, we will confirm its accuracy against gold-standard brain autopsy findings in PSP and related diseases using samples from  leading programs in the USA and Canada. Second, we will evaluate the test in living participants enrolled in our ongoing IMAGINE study, where individuals undergo brain imaging, blood tests, and clinical assessments. Skin biopsies will be collected at two time points, one year apart, to assess whether the test can track disease progression over time. Finally, we will examine how this test can be combined with imaging and blood biomarkers to improve patient identification for clinical trials.

If validated, this approach could provide an accurate, affordable, and widely accessible biomarker to improve diagnosis in routine care and accelerate the development of new treatments for PSP.